Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MMP1 | P03956 | 9/20 | 0.53 |
| ▸ | MMP3 | P08254 | 8/20 | 0.53 |
| ▸ | MMP9 | P14780 | 7/20 | 0.53 |
| ▸ | MMP13 | P45452 | 6/20 | 0.53 |
| ▸ | MMP7 | P09237 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127264 | 1.00 | LMNA (0.54) | LMNAMMP1MMP3MMP9MMP13 | |
| SCHEMBL7121377 | 0.85 | L3MBTL1 (0.59) | ALDH1A1TSHR | |
| SCHEMBL7121380 | 0.85 | L3MBTL1 (0.59) | ALDH1A1TSHR | |
| SCHEMBL3832921 | 0.85 | NPSR1 (0.55) | LMNAALDH1A1MAPTTSHR | |
| SCHEMBL3832918 | 0.85 | NPSR1 (0.55) | LMNAALDH1A1MAPTTSHR | |
| SCHEMBL7127875 | 0.82 | CA1 (0.50) | ALDH1A1 | |
| SCHEMBL7127867 | 0.82 | CA1 (0.50) | ALDH1A1 | |
| SCHEMBL6652989 | 0.78 | MMP2 (0.61) | LMNAALDH1A1MAPTMMP2 | |
| SCHEMBL12290171 | 0.78 | RORC (0.60) | LMNAMMP1MMP3MMP9MMP13 | |
| SCHEMBL7128095 | 0.78 | HSD11B1 (0.52) | MMP1MMP3MMP9MMP13MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153771-A1 | Large scale synthesis of optically pure aziridines | LEXICON PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153771-A1 | Large scale synthesis of optically pure aziridines | QDPR, AZI2, NISCH | LMNA 4339/4885MMP1 4314/4885MMP3 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.